澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

PERCHERON FPO

0.004

0.000

成交量：137.50万

成交额：5,500

市值：728.97万

市盈率：-0.98

高：0.004

开：0.004

低：0.004

收：0.004

52周最高：0.010

52周最低：0.002

股本：18.22亿

流通股本：8.17亿

量比：0.82

换手率：0.17%

股息：- -

股息率：- -

每股收益(TTM):-0.004

每股收益(LYR):-0.004

净资产收益率：-54.66%

总资产收益率：-28.90%

市净率：0.97

市盈率(LYR):-0.98

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

Percheron Therapeutics寻求停牌，拟融资以资助与范德比尔特健康的合作研究

Percheron Therapeutics Ltd——范德比尔特健康中心将开展Hmbd-002治疗急性髓系白血病的临床试验

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/PER.AU"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PER.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PER.AU\",,,,,undefined,":{"symbol":"PER.AU","market":"AU","secType":"STK","nameCN":"PERCHERON FPO","latestPrice":0.004,"timestamp":1791781920000,"preClose":0.004,"halted":0,"volume":1375000,"delay":0,"changeRate":0,"nameEN":"PERCHERON FPO","floatShares":816628906,"shares":1822415536,"eps":-0.0041,"marketStatus":"未开盘","change":0,"latestTime":"10-12 16:12:00 AEDT","open":0.004,"high":0.004,"low":0.004,"amount":5500,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0041,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1791846000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.004,"openAndCloseTimeList":[[1791759600000,1791781200000]],"volumeRatio":0.8188118783190138,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PER.AU","preClose":0.004,"auctionPrice":0.004,"auctionVolume":125000,"auction":3,"marketStatus":"盘后竞价","timestamp":1791781200870}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PER.AU\",,,,,undefined,":{"symbol":"PER.AU","floatShares":816628906,"roa":"-28.90%","roe":"-54.66%","lyrEps":-0.0041,"volumeRatio":0.8188118783190138,"shares":1822415536,"dividePrice":0,"high":0.004,"amplitude":0,"preClose":0.004,"low":0.004,"week52Low":0.002,"pbRate":"0.97","psRate":"8.64","week52High":0.01,"institutionHeld":0,"latestPrice":0.004,"eps":-0.0041,"divideRate":0,"volume":1375000,"delay":0,"ttmEps":-0.0041,"open":0.004,"prevYearClose":0.009,"prevWeekClose":0.004,"prevMonthClose":0.005,"prevQuarterClose":0.005,"fiveDayClose":0.004,"twentyDayClose":0.004,"sixtyDayClose":0.003},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PER.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PER.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PER.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1139987884","title":"Percheron Therapeutics寻求停牌，拟融资以资助与范德比尔特健康的合作研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1139987884","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139987884?lang=zh_cn&edition=fundamental","pubTime":"2026-08-28 07:03","pubTimestamp":1787871792,"startTime":"0","endTime":"0","summary":"Percheron Therapeutics宣布，已申请股票交易停牌，此举旨在推进一项资本筹集计划，为与范德比尔特健康（Vanderbilt Health）合作开展的研究项目提供资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PER.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151077858","title":"Percheron Therapeutics Ltd——范德比尔特健康中心将开展Hmbd-002治疗急性髓系白血病的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1151077858","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151077858?lang=zh_cn&edition=fundamental","pubTime":"2026-08-28 06:12","pubTimestamp":1787868773,"startTime":"0","endTime":"0","summary":"Percheron Therapeutics Ltd宣布，范德比尔特健康中心将主导一项针对Hmbd-002的临床试验，该试验聚焦于急性髓系白血病的治疗。此次与范德比尔特健康中心的携手，有望为急性髓系白血病患者带来新的治疗选择。临床试验的具体细节尚未完全披露，但此举无疑凸显了Percheron Therapeutics在肿瘤学领域的持续深耕。急性髓系白血病是一种进展迅速的血癌，现有治疗方案有限，且复发风险较高。Percheron Therapeutics此番布局，正是瞄准了这一未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PER.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PER.AU\",params:#limit:6,delay:true,,,undefined,":[]}}